Seres Therapeutics Appoints Interim CEO, Restructures Leadership Team with Key Promotions and Substantial Equity Grants

summarizeSummary

Seres Therapeutics announced a major leadership overhaul, appointing an Executive Chair and Interim CEO, promoting its Chief Scientific Officer to President, and its Senior Vice President of Clinical Development to COO, accompanied by significant compensation packages including substantial equity grants.

check_boxKey Events

• Interim CEO and Executive Chair Appointed

  Richard N. Kender, a current board member, was appointed Executive Chair of the Board and Interim Chief Executive Officer, effective March 2, 2026. He will receive an annual base salary of $520,000, a target annual bonus of 55%, and a one-time signing bonus of $250,000.

• Key Executive Promotions

  Matthew Henn, Ph.D., Chief Scientific Officer, was promoted to the additional role of President. Kelly Brady, M.S., Senior Vice President, Clinical Development, was promoted to Executive Vice President, Chief Operating Officer. Both appointments are effective March 2, 2026.

• Former Co-CEOs Step Down from Leadership Roles

  Thomas J. DesRosier and Marella Thorell ceased serving as Co-Presidents and Co-Chief Executive Officers. Mr. DesRosier continues as Chief Legal Officer, and Ms. Thorell continues as Chief Financial Officer.

• Substantial Equity and Cash Incentives

  The company granted options to purchase 200,000 shares to Mr. Kender, 100,000 shares to Dr. Henn, and 75,000 shares to Ms. Brady. Dr. Henn and Ms. Brady also received one-time retention bonuses of $230,000 each. A portion of these options is contingent on stockholder approval of a plan amendment.

auto_awesomeAnalysis

This 8-K details a significant leadership restructuring at Seres Therapeutics. The appointment of an Executive Chair and Interim CEO, alongside the promotion of two other key executives, signals a major transition for the company. The substantial equity grants (options to purchase 375,000 shares) and cash bonuses totaling $710,000 for these executives represent a significant investment in new leadership and retention. While these compensation packages are a cost to the company and could lead to notable dilution if all options are exercised, they are intended to stabilize and incentivize the leadership team during this period of change. The interim nature of the CEO role suggests the company is navigating a transition and is likely searching for a permanent solution.